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Objectives To obtain information on the microbiology workload, etiology and antimicrobial susceptibility of
urinary tract infection (UTI) pathogens isolated in European hospitals.
Materials andmethods We collected data available in the microbiology units of a large sample of European
hospitals regarding the laboratory workload, diagnostic criteria, and etiology and antimicrobial resistance of
the urinary isolates collected on one day (the study day).
Results Data were received from a total of 228 hospitals from 29 European countries. The average rate of urine
samples cultured per 1000 admissions in 1999 was 324. The criteria to consider a positive urine culture as
significant were quite variable;104 colony-forming units (CFU)/mL for bacteria or103 CFU/mL in the
case of yeasts were the most used cut-off points. On the study day, a total of 607 micro-organisms from 522
patients with nosocomial UTI were isolated. The six most commonly isolated micro-organisms were, in
decreasing order: Escherichia coli (35.6%), Enterococci (15.8%), Candida (9.4%), Klebsiella (8.3%), Proteus (7.9%)
and Pseudomonas aeruginosa (6.9%). Pseudomonas was isolated more frequently in non-EU countries. The
study data reveal high rates of antimicrobial resistance in UTI pathogens, especially in non-EU countries,
where Pseudomonas aeruginosa presented rates of aminoglycoside resistance as high as 72% to gentamicin,
69.2% to tobramycin and 40% to amikacin.
Conclusions Nosocomial UTI accounts for an important proportion of the workload in microbiology
laboratories. A consensus on the practice and interpretation of urine cultures in Europe is needed. The levels
and patterns of resistance of UTI pathogens must be a serious cause for concern and a clear reason for
stricter guidelines and regulations in antimicrobial policy.
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INTRODUCTION
Information relative to urinary tract infections (UTI) in patients
hospitalised in European institutions is fragmentary and scarce,
and generally comes from partial studies that are usually influ-
enced by certain types of patient or particular micro-organisms
[1–4]. The diagnostic criteria used to report significant urine
cultures with microbial growth in different institutions are
unknown on a broad European basis [5].
The shift in the etiology of different infections detected in the
last decade has not been assessed in the field of UTI with a large
population sample, despite the fact that this infection is the most
frequent nosocomial infection, thereby influencing greatly the
sampling of nosocomial pathogens [2,3,6,7]. Finally, there are
no studies comparing microbiological data on UTI between
EU and non-EU countries.
The aim of this European Study Group on Nosocomial
Infections (ESGNI) of the European Society of Clinical Micro-
biology and Infectious Diseases (ESCMID) study was to deter-
mine the (one-day) prevalence of nosocomial UTI in Europe
and to obtain information on the microbiology workload,
etiology and antimicrobial susceptibility of UTI pathogens.
This study is complemented by ESGNI-004 which deals
with the clinical aspects of nosocomial UTI (published in this
same issue).
MATERIALS AND METHODS
ESGNI-003 was a one-day (29 February 2000) prevalence
study that included a questionnaire which was sent to the
microbiology laboratories of every European hospital with
one or more ESCMID members.
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The questionnaire requested information on the population
served by the hospital, total number of beds, total number of
admissions, total number of urine samples processed, total
number of non-significant samples and total number of sig-
nificant positive samples (>105 CFU/mL) throughout the year
1999. Furthermore, information on the different cut-off values
used for positivity in each laboratory both for bacterial and yeast
infections, was requested.
The following study data were collected: total number of
urine samples reported positive or negative that day, positive
samples with one or two isolated species according to three
different diagnostic cut-off points, and number of ‘positive’
samples according to microbiology laboratory criteria. For each
episode of nosocomially acquired UTI (NAUTI) we requested
information regarding the micro-organisms present and the
antibiotic susceptibility profile regardless of the laboratory
method used to detect it. The list of antimicrobials included:
ampicillin, amoxicillin-clavulanate, methicillin, cefazolin, cefu-
roxime, cefotaxime, ceftazidime, cefepime, nitrofurantoin, imi-
penem, cotrimoxazole, ciprofloxacin, gentamicin, tobramycin,
amikacin, clindamycin, and vancomycin.
Definitions used
NAUTI was defined as the occurrence of any UTI beginning at
least 48 h after admission and a minimum of 105 colony-
forming units (CFU)/mL of at least one isolate and no more
than two isolates. More were regarded as contamination and
were not included. In the case of yeast isolates we considered
positive growth as more than 103 CFU/mL.
Data analysis
Continuous variables were expressed as the mean and standard
deviation (SD), and discrete variables as percentages. Student’s
unpaired t-test was used to compare continuous variables, the
Mann–Whitney U-test was used to compare continuous
variables not normally distributed, and the w2 or Fisher exact
test was used to compare proportions. All statistical tests were
two-tailed.
RESULTS
A total of 228 hospitals from 29 countries participated in the
study (Table 1), 149 hospitals from 13 EU countries and 79
institutions from 16 non-EU countries.
Laboratory workload of UTI during 1999
Of the 228 participating institutions, 67.7% were teaching and
32.3% were non-teaching institutions. Hospital sizes varied
from 500 beds (42%), to 501–1000 beds (34.3%) and
>1000 beds (23.7%). Overall, the estimated population served
by these institutions was 153 388 000 and the number of
estimated admissions during 1999 was 7 535 260.
The results of the questionnaire with regard to the micro-
biology workload in 1999 are shown in Table 2. The total
number of urine samples obtained for culture during 1999
was 2 448 370, or 324 per 1000 admissions. A total of 22.5%
of all urine samples grew one or two micro-organisms. Overall,
Table1 Participating hospitals
Country
No. of
participating
hospitals (%) Country
No. of
participating
hospitals (%)
Andorra 1 (0.4) Lithuania 1 (0.4)
Austria 8 (3.5) the Netherlands 5 (2.2)
Belgium 15 (6.6) Poland 18 (7.9)
Bulgaria 3 (1.3) Portugal 7 (3.1)
Croatia 8 (3.5) Romania 3 (1.3)
Czech Republic 9 (3.9) Russia 2 (0.9)
Denmark 1 (0.4) Serbia 1 (0.4)
Estonia 1 (0.4) Slovak Republic 5 (2.2)
Finland 1 (0.4) Slovenia 3 (1.3)
France 15 (6.6) Spain 40 (17.5)
Germany 17 (7.5) Sweden 1 (0.4)
Greece 17 (7.5) Switzerland 6 (2.6)
Hungary 5 (2.2) Turkey 12 (5.3)
Italy 17 (7.5) United Kingdom 5 (2.2)
Latvia 1 (0.4) TOTAL 228
Table 2 Microbiology workload in1999 according to questionnaire results
EUcountries (n¼149) Non-EU countries (n¼79) Total (n¼228)
Total urine samples 1857608 590762 2448370
Total no. admissions 4738945 2796311 7535256
Urine sample/1000 ad. yeara 392 211.3 324
Positive samples (%) 434782 (23.4%) 122478 (20.7%) 557260 (22.7%)
a ad. year, admissions per year.
P<0.05.
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EU centers received significantly more urine samples per
1000 admissions and had a significantly higher rate of ‘positivity’
(¼ urine culture with clinically significant growth).
Criteria used to assess the significance of urine cultures in
different institutions
Of all the institutions surveyed, 19% (22.5% in EU countries
versus 12.2% in non-EU countries) select urines for culture
whereas the remaining 81% process all urines without screen-
ing. Similarly, 24.3% of all laboratories test for growth inhibitors
in their urine samples. In this regard, differences between EU
and non-EU countries were not statistically significant.
The cut-off values used to consider a voided sample as
potentially significant in each institution were variable and
are summarised in Table 3. The majority of institutions con-
sidered counts of 104 CFU/mL as clinically significant,
particularly in the presence of leukocyturia. To define UTI,
the criterion of leukocyturia was significantly more often used
in EU countries (20.6% versus 4.1%; P< 0.05). Overall, only
27.4% of the participating institutions used the Kass count of
105 CFU/mL to define bacterial UTI.
In the case of candiduria (see Table 4), the majority of the
laboratories considered a sample as positive when the count was
103 CFU/mL (68.9%), particularly when white blood cells
were present in the urine sediment.
Only 14.7% of the hospitals regularly performed antimicro-
bial sensitivity testing on all isolates from urine samples with low
counts [103104], although the majority (83.5%) tested a subset
of isolates for their antimicrobial sensitivity.
A clinical consultation with the attending physician was
initiated frequently (36.4%), sometimes (59.2%), or never
(4.4%) by the participating microbiologists/infectious diseases
service.
Microbiology results
Data regarding microbiology workload on the study day are
largely in accordance with the questionnaire data from 1999.
On the study day, 5152 urine samples were taken in 228
institutions. Assuming a steady number of admissions in the
year 2000, the estimated number of urine samples during the
day-prevalence-study was 249 per 1000 admissions. Table 5
summarises the positivity rates according to different cut-offs:
954–1662 samples were positive (18.5–32%). If we accept the
specific criteria of the individual laboratories, overall, 21.4% of
the urines cultured were considered positive, with no significant
differences between EU and non-EU countries.
The number of micro-organisms isolated from significant
nosocomially acquired bacteriuria episodes on the study day was
607 from 522 patients (Table 6). The six most commonly
isolated micro-organisms were, in decreasing order: Escherichia
coli, Enterococcus sp., Candida sp., Klebsiella sp., Proteus sp. and
Pseudomonas aeruginosa. Overall, 14.6% of the episodes were
polymicrobial (12.7% in EU countries versus 19.7% in non-EU
countries; P¼ 0.053). Gram-negative bacteria represented
Table 3 Cut-off values used for positive voided urine cultures (bacteria)
EUcountries
(n¼149)
Non EU countries
(n¼79)
Total
(n¼228)
>1000 CFU/mL 9.2% 10.8% 9.8%
>1000 CFU/mLþWBCa 17.7% 13.5% 16.3%
>10000 CFU/mL 31.2% 32.4% 31.6%
>10000 CFU/mLþWBC 20.6% 4.1% 14.9%
>100000 CFU/mL 21.3% 39.2% 27.4%
aWBC, white blood cells.
P<0.05.
Table 4 Cut-off values used for positive voided urine cultures (Candida)
EUcountries
(n¼149)
Non-EU countries
(n¼79)
Total
(n¼228)
>1000 CFU/mL 19% 26% 21.5%
>1000 CFU/mLþWBCa 48.5% 45.2% 47.4%
>10000 CFU/mL 11% 6.8% 9.6%
>10000 CFU/mLþWBC 14.7% 16.4% 15.3%
>100000 CFU/mL 6.6% 5.5% 6.2%
aWBC, white blood cells.
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68.5% of all isolates, and Gram-positive represented 22.1%.
Yeasts were isolated from 9.4% of urine samples. The type
of micro-organism was comparable between both groups of
hospitals (EU and non-EU) with the single exception of
Pseudomonas aeruginosa which was isolated more frequently in
non-EU countries (P¼ 0.04).
Resistance patterns of themost frequent isolates
Antibiotic resistance data of UTI isolates from the different
centers are depicted in Tables 7 and 8. The sensitivity assays were
not performed in a central laboratory and local results of
susceptibility testing were taken at face-value. In the case of
E. coli, 54.8% of isolates were resistant to ampicillin, 14.2% were
resistant to amoxicillin-clavulanate (25.4% in non-EU countries
versus 9.4% in EU countries, P¼ 0.01), 28% were resistant to
cotrimoxazole, 9% to ciprofloxacin and 5.8% to gentamicin
(19.5% in non-EU countries versus 1.4% in EU countries,
P< 0.0001). Imipenem-resistant P. aeruginosa was reported in
13.5% of the isolates; ciprofloxacin resistance occurred in 42.9%
(63.2% in non-EU countries versus 26.1% in EU countries,
P¼ 0.028) and P. aeruginosa isolates presented high rates of
aminoglycoside resistance: 46% to gentamicin (72% in non-
EU countries versus 32.8% in EU countries, P¼ 0.004) and
35.3% to tobramycin (69.2% in non-EU countries versus 14.3%
in EU countries, P¼ 0.02), with amikacin as the antimicrobial
with the lowest rates of resistance (19.4%; 40% in non-EU
countries versus 4.7% in EU countries, P¼ 0.02). Ampicillin
resistance in Enterococcus sp. was detected in 14.6% of the isolates
(11/13 resistant isolates were Enterococcus faecium and 2/13 were
Enterococcus sp.) and only one isolate of E. faecium was vanco-
mycin-resistant. Global resistance rates in Gram-negative and
Gram-positive organisms other than Enterococcus are presented
in Table 8.
Table 5 Data regarding the study day (29 February 2000)
EU countries
(n¼149)
Non-EU countries
(n¼79)
Total
(n¼228)
Total urine samples 3442 1710 5152
Total positive samples (one or two species)
Cut-off point:
>103 CFU/mL 912 (26.5%) 750 (43.9%) 1662 (32%)
>104 CFU/mL 758 (22%) 639 (37.4%) 1397 (27%)
>105 CFU/mL 650 (19%) 304 (18%) 954 (18.5%)
Samples with more than two species 259 (7.5%) 116 (6.8%) 375 (7.3%)
Considered significant (microbiology laboratory criteria) 732 (21.3%) 373 (21.8%) 1105 (21.4)
P<0.05.
Table 6 Micro-organisms most frequently (>1%) isolated from urine samples
EU countries
(n¼421)
Non-EU countries
(n¼186)
Total
(n¼607)
Escherichia coli 156 (37.4%) Escherichia coli 56 (30.6%) Escherichia coli 216 (35.6%)
Enterococcus sp. 70 (16.8%) Enterococcus sp. 26 (14.2%) Enterococcus sp. 96 (15.8%)
Candida sp. 41 (9.8%) Pseudomonas aeruginosa 19 (10.4%) Candida sp. 57 (9.4%)
Klebsiella sp. 35 (8.4%) Proteus sp. 18 (9.8%) Klebsiella sp. 50 (8.3%)
Proteus sp. 30 (7.2%) Candida sp. 16 (8.7%) Proteus sp. 48 (7.9%)
Pseudomonas aeruginosa 23 (5.5%) Klebsiella sp. 14 (7.7%) Pseudomonas aeruginosa 42 (6.9%)
Enterobacter sp. 16 (3.8%) Acinetobacter sp. 5 (2.7%) Enterobacter sp. 21 (3.5%)
Staphylococcus aureus 9 (2.2%) Citrobacter sp. 5 (2.7%) Staphylococcus aureus 14 (2.3%)
CNS 8 (1.9%) CNS 5 (2.7%) CNS 13 (2.1%)
Citrobacter sp. 7 (1.7%) Staphylococcus aureus 5 (2.7%) Citrobacter sp. 12 (2%)
Acinetobacter sp. 6 (1.4%) Enterobacter sp. 4 (2.2%) Acinetobacter sp. 11 (1.8%)
Morganella sp. 5 (1.2%) Streptococcus agalactiae 3 (1.6%)
P¼0.03.
CNS, coagulase-negative staphylococci.
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DISCUSSION
The majority of references in the classic books on clinical
microbiology, infectious diseases and laboratory medicine give
no insights into the workload generated by urine culture
sampling in microbiology laboratories [8–10]. Our data,
obtained from 228 hospitals in Europe, show that 324 urine
cultures were processed per 1000 admissions in 1999, with a
significant difference between the workload in EU and non-EU
hospitals. EU hospitals process a larger number of samples per
year. Only 19% of hospitals use screening criteria either to
select urine for culture or to complete the culture results, with a
trend towards more screening in EU countries. Such proce-
dures include pyuria detection [11], dipstrips for nitrites and
Table 7 Individual micro-organisms percentage of antibiotic resistance
Non-EUcountries EU countries Total
Antibiotics no. tested % no. tested % no. tested % P value
Escherichia coli Total: 56 Total: 156 Total: 212
Cotrimoxazole 15/49 30.6 30/113 26.5 45/162 28
Ampicillin 29/50 58 81/151 53.6 110/201 54.8
AM-CLAV 14/55 25.4 13/138 9.4 27/193 14.2 0.01
Ciprofloxacin 4/48 8.3 14/153 9.1 18/201 9
Gentamicin 9/46 19.5 2/141 1.4 11/187 5.8 0.0001
Pseudomonas aeruginosa Total: 19 Total: 23 Total: 42
Ceftazidime 3/19 15.8 2/21 9.5 5/40 12.5
Cefepime 2/13 15.4 1/13 7.7 3/26 11.5
Imipenem 2/16 12.5 3/21 14.3 5/37 13.5
Ciprofloxacin 12/19 63.2 6/23 26.1 18/42 42.9 0.028
Gentamicin 13/18 72 5/21 23.8 18/39 46 0.004
Tobramycin 9/13 69.2 3/21 14.3 12/34 35.3 0.02
Amikacin 6/15 40 1/21 4.7 7/36 19.4 0.02
Enterococcus sp. Total: 26 Total: 70 Total: 96
Ampicillin 3/24 12.5 10/65 15.4 13/89 14.6
Vancomycin 0/18 0 1/56 1.8 1/74 1.35
Ciprofloxacin 8/16 50 25/56 44.6 33/72 45.8
Table 8 Global resistance rates
Antimicrobials
tested
Gram-negative
bacteria Escherichia coli Pseudomonas Enterococcus
Other Gram-positive
bacteriab
Cotrimoxazole 32.4%a 28% 18.7%
Ampicillin 66%a 54.8% 14.6% 48%
AM-CLAV 29%a 14.2% 33%
Cefotaxime 14.6%a 3.8%
Ceftazidime 15% 12.5%
Cefepime 9.5% 11.5%
Imipenem 2.8% 13.5%
Ciprofloxacin 16.7% 9% 42.9% 45.8% 51.6%
Gentamicin 17.8% 5.8% 46% 46.8%
Tobramycin 17% 35.3%
Amikacin 7.5% 19.4%
Oxacillin 56.6%
Vancomycin 1.3% 3%
aRates excluding P. aeruginosa (not tested).
bApart from Enterococcus.
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leukocyte esterase [12,13], microscopy and, more recently,
automated systems for bacteriuria and pyuria detection [14–
25]. The questionnaire data showed a wide range of cut-off
values to define clinically significant bacteriuria in the different
laboratories and countries. The positivity rate in urine at
different cut-off values ranged from 32% for 103 CFU/mL
to 18.5% for 105 CFU/mL. Based on the individual cut-off
values of the participating laboratories, 21.4% of all urine
cultures showed clinically significant growth (Table 5).
Since Kass established that a count of 105 CFU/mL urine
of one bacterial species is clinically significant in women
suffering from pyelonephritis or non-symptomatic bacteriuria,
growth of a significant number of CFU seems to be the main
criteria in diagnosing UTI [26,27]. As these cut-off values were
defined for specific populations, they cannot simply be extra-
polated to other groups of patients or different clinical situa-
tions. Therefore, various definitions and cut-off values for UTI
have been evaluated over the last 20 years. Bacterial counts of
104/mL must be considered clinically significant in women
with symptomatic bacteriuria [28–30], and occasionally in men
[31] and catheterised patients [28,32]. For yeasts, adequate cut-
off values are not clearly defined [33,34]. In the European
microbiology laboratories participating in this study,104105
CFU/mL for bacteria and 103 CFU/mL for yeasts were the
most frequently used cut-off values.
During the last few years, many studies have revealed changes
in the etiology of nosocomial infection [35]. With the excep-
tion of the study by Dornbusch et al. [36], which was designed
to detect antimicrobial resistance, only local/single center data
on nosocomial UTI are available [6, 37–40]. In the present
study, E. coli, Enterococcus sp. and Candida species were, in
decreasing order, the top three pathogens isolated from patients
with nosocomial UTI. This agrees with data from other studies
that report an increase in the number of Gram-positive bacteria
and yeasts as nosocomial UTI pathogens [6,39]. Staphylococcus
aureus was the second most common Gram-positive pathogen
isolated responsible for nosocomial UTI in this European study.
With the exception of P. aeruginosa, which was more frequently
isolated among non-EU patients, the distribution of UTI
pathogens was comparable between EU and non-EU countries.
This fact had already been reported by Dornbusch et al. [36] in
nosocomial UTI. Furthermore, the differences between EU
and non-EU countries with regard to the prevalence of P.
aeruginosa as a nosocomial pathogen have also been reported in
the ESGNI 001 and 002 studies (bloodstream infections) [41].
The antimicrobial resistance patterns of the study isolates
confirm the changes reported in nosocomial pathogens from
other sources [36,42–44], but the data should be interpreted
with caution, because susceptibility testing was not confirmed
by uniform methods in a central laboratory and the number of
isolates is limited. Nevertheless, certain trends can be seen and
are of interest. Resistance to ampicillin, one of the most
commonly used agents for the empirical treatment of UTIs,
was as high as 54.8% in the case of E. coli. The overall resistance
rate to ampicillin in Gram-negatives was 66%. Twenty-one
per cent of the E. coli isolates were resistant to cotrimoxazole;
a resistance rate similar to those from other European studies
[36,42] and higher than those reported from the USA
[35].
Pseudomonas aeruginosa isolates from non-EU countries
showed resistance rates of over 50% for quinolone and ami-
noglycoside antibiotics (except for amikacin), thereby posing a
major problem in the management of nosocomial UTI in
hospitals in these regions. One of the causes of this problem
could be a deficient antimicrobial policy. This fact was first
noticed in a study on the susceptibility of blood and urine
isolates from several European hospitals during 1992 and 1993.
In this study, gentamicin-resistance in P. aeruginosa was reported
in more than 67% of laboratories from the former Eastern Bloc
[36].
This study, ESGNI-003, provides an estimation of the cur-
rent microbiology laboratory situation with regard to the
diagnosis and prevalence of nosocomial UTI in Europe. It is
clear that UTIs represent an important proportion of work-
load in microbiology laboratories. From our point of view, a
consensus on the practice and interpretation of urine cultures in
Europe needs to be considered. Finally, the levels and patterns of
resistance of UTI pathogens must be a serious cause for concern
and a reason for stricter guidelines and regulations in antimi-
crobial policy.
REFERENCES
1. Anichini P, Bordonaro P, Fontanelli A, Nicoletti P. Frequency and
antibiotic susceptibility of urinary pathogens isolated in the
microbiology and virology laboratory of the Careggi General
Hospital in the period July – December, 1996. Minerva Urol Nefrol
1999; 51 (4): 217–26.
2. Arosio A, Ferrari S, Tranchina G, Borroni M, Grassi L. Urinary
tract infections in a general medicine department. Comments
on cases collected over 3 years. Minerva Med 1986; 77 (28–29):
1339–46.
3. Papapetropoulou M, Pagonopoulou O, Kouskouni E. Prevalence
and sensitivity to antibiotics of Enterobacteriaceae isolated from
urinary cultures in some microbiology laboratories of a city in
west Greece. Pathol Biol (Paris) 1997; 45 (9): 716–20.
4. Munzinger J, Buhler M, Geroulanos S, Luthy R, von Graevenitz
A. Nosocomial infections in a University hospital. Results of a
prospective study of infections in a medical and surgical ward and a
surgical intensive care unit. Schweiz Med Wochenschr 1983; 113
(48): 1782–90.
5. Koivula T, Gronroos P, Gavert J et al. Basic urinalysis and urine
culture: Finnish recommendations from the working group on
clean midstream specimens. Scand J Clin Lab Invest Suppl 1990;
200: 26–33.
6. Bronsema DA, Adams JR, Pallares R, Wenzel RP. Secular trends
in rates and etiology of nosocomial urinary tract infections at a
University hospital. J Urol 1993; 150 (2 Part 1): 414–16.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 523–531
528 Clinical Microbiology and Infection, Volume 7 Number 10, October 2001
7. Meares EM Jr. Nosocomial infection of urinary tract: changing
pathogens, changing patterns. Urology 1985; 26 (Suppl. 1): 2–4.
8. Mandell DB. Principles and practice of infectious diseases, Vol. 1, 5th
edn. Philadelphia: Churchill Livingstone, 2000.
9. Murray JB. Manual of clinical microbiology, Vol. 1, 7th edn.
Washington DC: ASM Press, 1999.
10. Clarridge JPMTV, KL. Cumitech 2A, laboratory diagnosis of urinary
tract infection. Washington DC: A.S.Weissfeld. ASM Press, 1998.
11. Stamm WE. Measurement of pyuria and its relation to bacteriuria.
Am J Med 1983; 75 (1B): 53–8.
12. Pfaller MA, Koontz FP. Laboratory evaluation of leukocyte
esterase and nitrite tests for the detection of bacteriuria. J Clin
Microbiol 1985; 21 (5): 840–2.
13. Pfaller M, Ringenberg B, Rames L, Hegeman J, Koontz F. The
usefulness of screening tests for pyuria in combination with
culture in the diagnosis of urinary tract infection. Diagn Microbiol
Infect Dis 1987; 6 (3): 207–15.
14. Pezzlo M. Detection of urinary tract infections by rapid methods.
Clin Microbiol Rev 1988; 1 (3): 268–80.
15. Shaw KN, McGowan KL. Evaluation of a rapid screening filter
test for urinary tract infection in children. Pediatr Infect Dis J 1997;
16 (3): 283–7.
16. Kunin CM, Buesching WJ. Novel screening method for urine
cultures using a filter paper dilution system. J Clin Microbiol 2000;
38 (3): 1187–90.
17. Bixler Forell E, Bertram MA, Bruckner DA. Clinical evaluation of
three rapid methods for the detection of significant bacteriuria. J
Clin Microbiol 1985; 22 (1): 62–7.
18. Semeniuk H, Church D. Evaluation of the leukocyte esterase and
nitrite urine dipstick screening tests for detection of bacteriuria in
women with suspected uncomplicated urinary tract infections. J
Clin Microbiol 1999; 37 (9): 3051–2.
19. Winquist AG, Orrico MA, Peterson LR. Evaluation of the
cytocentrifuge Gram stain as a screening test for bacteriuria in
specimens from specific patient populations. Am J Clin Pathol
1997; 108 (5): 515–24.
20. Vickers D, Ahmad T, Coulthard MG. Diagnosis of urinary tract
infection in children: fresh urine microscopy or culture? [see
comments]. Lancet 1991; 338 (8770): 767–70.
21. Rouse DJ, Andrews WW, Goldenberg RL, Owen J. Screening
and treatment of asymptomatic bacteriuria of pregnancy to
prevent pyelonephritis: a cost-effectiveness and cost-benefit
analysis [see comments]. Obstet Gynecol 1995; 86 (1): 119–23.
22. Hagay Z, Levy R, Miskin A, Milman D, Sharabi H, Insler V. Urisc-
reen, a rapid enzymatic urine screening test: useful predictor of signi-
ficant bacteriuria in pregnancy. Obstet Gynecol 1996; 87 (3): 410–13.
23. Preston A, O’Donnell T, Phillips CA. Screening for urinary tract
infections in a gynaecological setting: validity and cost-effective-
ness of reagent strips. Br J Biomed Sci 1999; 56 (4): 253–7.
24. Waisman Y, Zerem E, Amir L, Mimouni M. The validity of the
uriscreen test for early detection of urinary tract infection in
children. Pediatrics 1999; 104 (4): e41.
25. Flanagan PG, Rooney PG, Davies EA, Stout RW. Evaluation of
four screening tests for bacteriuria in elderly people [see
comments]. Lancet 1989; 1 (8647): 1117–19.
26. Kass EHFM. Asymptomatic infections of the urinary tract. Trans
Assoc Am Physicians 1956; 69: 56–64.
27. Pappas PG. Laboratory in the diagnosis and management of
urinary tract infections. Med Clin North Am 1991; 75 (2): 313–25.
28. Stamm WE. Protocol for diagnosis of urinary tract infection:
reconsidering the criterion for significant bacteriuria. Urology
1988; 32 (Suppl. 2): 6–12.
29. Kunin CM, White LV, Hua TH. A reassessment of the importance
of ‘low-count’ bacteriuria in young women with acute urinary
symptoms. Ann Intern Med 1993; 119 (6): 454–60.
30. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE.
Evaluation of new anti-infective drugs for the treatment of urinary
tract infection. Infectious Diseases Society of America and the
Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl. 1):
S216–27.
31. Lipsky BA. Urinary tract infections in men. Epidemiology,
pathophysiology, diagnosis and treatment. Ann Intern Med 1989;
110 (2): 138–50.
32. Stark RP, Maki DG. Bacteriuria in the catheterized patient. What
quantitative level of bacteriuria is relevant? N Engl J Med 1984;
311 (9): 560–4.
33. Goldberg PK, Kozinn PJ, Wise GJ, Nouri N, Brooks RB.
Incidence and significance of candiduria. JAMA 1979; 241 (6):
582–4.
34. Febre N, Silva V, Medeiros EA, Wey SB, Colombo AL, Fischman
O. Microbiological characteristics of yeasts isolated from urinary
tracts of intensive care unit patients undergoing urinary
catheterization. J Clin Microbiol 1999; 37 (5): 1584–6.
35. Jones RN. Impact of changing pathogens and antimicro-
bial susceptibility patterns in the treatment of serious infec-
tions in hospitalized patients. Am J Med 1996; 100 (6A):
3S–12S.
36. Dornbusch K, King A, Legakis N. Incidence of antibiotic
resistance in blood and urine isolates from hospitalized patients.
Report from a European collaborative study. European Study
Group on Antibiotic Resistance (ESGAR). Scand J Infect Dis 1998;
30 (3): 281–8.
37. Chan RK, Lye WC, Lee EJ, Kumarasinghe G. Nosocomial
urinary tract infection: a microbiological study. Ann Acad Med
Singapore 1993; 22 (6): 873–7.
38. Weber G, Riesenberg K, Schlaeffer F, Peled N, Borer A, Yagupsky
P. Changing trends in frequency and antimicrobial resistance of
urinary pathogens in outpatient clinics and a hospital in Southern
Israel, 1991–95. Eur J Clin Microbiol Infect Dis 1997; 16 (11):
834–8.
39. Corti G, Giganti E, Paradisi F, Nicoletti P. Urinary tract infections
in the city of Florence: epidemiological considerations over a
twenty-year period. Eur J Epidemiol 1993; 9 (3): 335–40.
40. Naber KG. [Infectiology of the urogenital tract. 5. Therapy of
complicated and nosocomial urinary tract infections and of
unusual pathogens – selection of antibiotics]. Fortschr Med 1997;
115 (16): 48–50.
41. Bouza EP-MJ, Mun˜oz P and the Cooperative Group of the
European Study Group on Nosocomial Infections. Report of
ESGNI01 and ESGNI02 studies. Bloodstream infections in
Europe. Clin Microbiol Infect 1999; 5 (Suppl. 2): 2S1–2S12.
42. Alo´s JI, Go´mez Garce´s JL, Garcı´a Bermejo I, Garcı´a Go´mez JJ,
Gonza´lez Palacios R, Padilla B. The prevalence of Escherichia coli
susceptibility to quinolones and other antibiotics in community-
acquired bacteriurias in Madrid. Med Clin (Barc) 1993; 101 (3):
87–90.
43. Dornbusch K. Resistance to beta-lactam antibiotics and cipro-
floxacin in gram-negative bacilli and staphylococci isolated from
blood: a European collaborative study. European Study Group on
Antibiotic Resistance [see comments]. J Antimicrob Chemother
1990; 26 (2): 269–78.
44. Cunney RJ, McNally RM, McNamara EM, al Ansari N, Smyth
EG. Susceptibility of urinary pathogens in a Dublin teaching
hospital. Ir J Med Sci 1992; 161 (11): 623–5.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 523–531
Bouza et al European perspective on nosocomial urinary tract infections I 529
APPENDIX 1. ESGNI0 0 3: AUTHORS
Dr Abb, Jochen (Ludwigsburg H, Germany); Dr Adam, Dieter
(Chu Munich. Germany); Dr Afonso, Teresa (C Hospitalier De
Funchal. Portugal); Dr Agulla, Andres (C.H.A. Marcide.
Spain); Dr Alain, Ros (Chu Saint Etienne. France); Dr Alonso,
Roberto (H.G.U. Gregorio Maran˜on. Spain); Dr Courtois,
Andre (Cnb Bruye`res. Belgium); Dr Ang, Ozdem (Istambul
Medical Faculty. Turkey); Dr Arosio, Marco (Ospedali Riuniti.
Italy); Dr Arribi, Ana (Severo-Ochoa. Spain); Dr Arta, Balode
(Stradina Cuh. Latvia); Dr Asboth, Friederike (Smz-Ost
Donauspital. Austria); Dr Aspiroz, Carmen (Hospital Comarcal
Alcan˜iz. Spain); Dr Aulami, Athina (Lainon Gh. Greece); Dr
Ausina, Vicente (H Germans Trias I Pujol. Spain); Dr Bakir,
Mehmet (Cumhuriyet University of Hastanesi. Turkey); Dr
Becker, Andrea (Karlsruhe H. Germany); Dr Bergerova,
Tamara (University Hospital Plzen. Czech Republic); Dr Ber-
nasconi, Enos (Ospedale Regionale Lugano. Switzerland); Dr
Bethimouti, Katerina (Redcross H. Greece); Dr Bille, Jacques
(Chu Vaubois. Switzerland); Dr Boggian, Katia (Kantonhospital
Sg. Switzerland); Dr Bonadio, Mario (S. Chiara H. Italy); Dr
Branislav, Tiodorovic (Clinical Center Nich. Serbia-Yug); Dr
Calado, Elsa (Hg San Antonio. Portugal); Dr Camporese,
Alessandro (Ao S.Maria Delli Angeli. Italy); Dr Casal Martinez,
Javier (Nostra Senyora Meritxell. Andorra); Dr Chemeralova,
Eva (Fhrih Ostrava. Czech Republic); Dr Christos, Mathas (Gh
Agia Olga. Greece); Dr Cisterna, Ramon (H Basurto. Spain);
Dr Clemenceau, Kahla (H Francois Quesnay. France); Dr
Croix, Jean-Claude (Center Hospital De Troyes. France); Dr
Croix, Jean-Claude (Les Hauts Clos. France); Dr Crotti,
Daniele (Ao Perugia. Italy); Dr Govaerts, Danielle (Chu Andre
Vesale. Belgium); Dr De Champs, Christophe (Chu Clermont-
Fd. France); Dr De Diego, Isabel (Hc Asturias. Spain); Dr De La
Rosa, M (Hu Virgen De Las Nieves. Spain); Dr Delmee,
Michel (Uh Saint Luc. Belgium); Dr Derkington, Petra (South-
mead H. United Kindom); Dr Donay, Jean Luc (Saint Louis
Hospital. France); Dr Drabu, Yasmin (North Middlesex H.
United Kindom); Dr Draghijeva, Elisaveta (Sofia Faculty Pedia-
trics Hospital Bulgaria); Dr Durmaz, Bengul (Inonu University
Hospital. Turkey); Dr Nagy, Elisabeth (Uh Szeged. Hungary);
Dr Ena, Javier (H Villajoyosa. Spain); Dr Esteban, Gloria (Santa
Maria Mai. Spain); Dr Fameree, Dominique (C.H.U. De
Charleroi. Belgium); Dr Feierl, Gebhard (Lkhu Graz. Austria);
Dr Fernandez, Maria and Dr Cristino, Melo (Santa Maria.
Portugal); Dr Ferrer, Isabel (Miguel Servet. Spain); Dr Findik,
Duygu (Medical Faculty Hospital. Turkey); Dr Fischer-Brugge,
Ulrich (Lc Nordhorn. Germany); Dr Fiser, Jerneja (Ph Sempeter.
Slovenia); Dr Fontana, Roberta (Uh Verona. Italy); Dr Fran-
genberg, Hans Reiner (Kreiskankenhaus H. Germany); Dr
Fuchs, Karl (Lkh Voecklabruck. Austria); Dr Gabriels, Patrick
(R.Z. Sint-Trudo. Belgium); Dr Galan, Isabel (Hc Melilla.
Spain); Dr Falagas, Matthew (Hygeia Hospital, Greece); Dr
Gantenberg, Rolf (Frankfurt H. Germany); Dr Garau, Javier
(H Mutua Terrassa. Spain); Dr Garcia De La Fuente, Celia (Hu
Marques De Valdecilla. Spain); Dr Garcı´a, Inma, Dr Rodriguez,
Juana and Dr Brezmes, Fe (Virgen De La Concha. Spain); Dr
Garrino, Maria-Grazia (Ucl Mont-Godinne. Belgium); Dr
Gedikoglu, Suna (Uludag University. Turkey); Dr Geppert,
Friederike (Krs Wien. Austria); Dr Gesu, Giovanni and Dr
Ossi, Cristi (H San Rafaele Milano. Italy); Dr Cartolano, Gian-
Luigi (Chg Poissy/St Germain. France); Dr Gismondo, Maria
Rita (L. Sacco Th. Italy); Dr Gomariz, Maria (Complejo
Hospitalario Don. Spain); Dr Gomez, Jose Luis (H Mostoles.
Spain); Dr Gomez, Victoria (Hg Virgen Del Rocio. Spain); Dr
Gordts, Bart (Az Sint January. Belgium); Dr Grassi, Carlos
(Xeral Cies. Spain); Dr Grise, Genevieve (C.H.I.Elbeuf-Lou-
viers. France); Dr Grmek, Irena (Gh Jesenice. Slovenia); Dr
Grzesiowski, Pawel (P1-P14. Poland); Dr Gubler, Jacques
(Stadtspital Triemli. Switzerland); Dr Guimaraes, Augusta
(Ipo Doposio. Portugal); Dr Gunaydin, Murat (Ondokuz
Mayis. Turkey); Dr Gur, Deniz (Hacettepe Uh. Turkey); Dr
Gutierrez, Jose (San Cecilio. Spain); Dr Halabi, Milo (Kh Ried
Innkreis. Austria); Dr Hanau, Beatrice (Lariboisie/Fernand
Widal. France); Dr Hascelik, Gulsen (Hacettepe University
Hospital Turkey); Dr Heininger, Ulrich (Ukbb. Switzerland);
Dr Hell, Markus (Gh Salzburg. Austria); Dr Hernaez, Silvia and
Dr Soler, Marta (Cu Navara. Spain); Dr Hernandez, Alberto
(Sant Jaume De Calella. Spain); Dr Hjalt, Carl-A˚ke (O¨stersunds
Lasarett. Sweden); Dr Holcikova, Alena (University Childrens
Hospital. Czech Republic); Dr Horova, Blanka (Bulovka Uni-
versity of. Hospital. Czech Republic); Dr Hosoglu, Salih (Dicle
University. Turkey); Dr Ceola, Iole and Dr Caciagli, Patrizio
(Ospedale S.Chiara-Trento. Italy); Dr Jajic-Bencic, Ines (Ch
Sestre Milosrdnice. Croatia); Dr Jane, Vlatka (Public Health
Care. Croatia); Dr Jansens, Hilde (University Hospital Antwe.
Belgium); Dr Brouillard, Jean (Rhms La Madeleine. Belgium);
Dr Minon, Jean-Marc (Les Cliniques De L’ipal. Belgium); Dr
Jezek, Petr (Mh Pribram. Czech Republic); Dr Kada, Helen
(Elena Velenzelou Gmh. Greece); Dr Kaltenis, Petras (Vilnius
Uch. Lithuania); Dr Kaminska, Wanda (Childrens Memorial.
Poland); Dr Kamotsay, Katalin (Su Budapest. Hungary); Dr
Kartali-Ktenidou, Sophia (Rguh Alexandeopolis. Greece); Dr
Kaysouzidou, Athiya (Idh Thessaloniki. Greece); Dr Kluyt-
mans, January (Ignatius. Netherlands); Dr Knausz, Marta
(Aladar Petz Ch. Hungary); Dr Kotulova, Daniela (Bratislava
Faculty Hospital. Slovak Republic); Dr Kouppari, Georgia (H
Amalia Fleming. Greece); Dr Koutsia-Carouzou, Chryssa
(Asclepeoin Voulas Gh. Greece); Dr Krcmery, Vladmir (Et.
Elisabeth. Slovak Republic); Dr Kucisec-Tepes, Nastja
(Gh Sueti Duh. Croatia); Dr Lampe, Anno (Leyenburg Hospi-
tal. Netherlands); Dr Lebessi, Evangelia (Pa Kyriakon Children
H. Greece); Dr Lindsay, Gavin (Southern General Hospital
Trust. UK); Dr Liskova, Anna (Regional Hospital Nitra.
Slovak Republic); Dr Lloret, Ana (H Arnau De Vilanova.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 523–531
530 Clinical Microbiology and Infection, Volume 7 Number 10, October 2001
Spain); Dr Luzzaro, Francesco (Ospedale Di Circolo. Italy); Dr
Malafiej, Eugeniusz (Polish Mothers Mem. Hospital Poland);
Dr Marchetti, Luciano (Ch Bollatesi. Italy); Dr Marroni,
Massimo (Azienda Ospedaliera. Italy); Dr Martin, Estrella
(Hu Velme. Spain); Dr Marty, Nicole (Chu Toulouse-Rangueil.
France); Dr Masoud, Helga (City Hospital Lainz. Austria); Dr
Mavridis, Anestis (Gh G.Hatzicosta. Greece); Dr Mertens, An
(Middelheim General Hospital. Belgium); Dr Meurman, Olli
(Turku University Hospital. Finland); Dr Mewis, Alex (Virga
Jesse Hospital. Belgium); Dr Viot, Michele (Center A Lacas-
sagne. France); Dr Miftode, Egidia (H Infectious Diseases.
Romania); Dr Miguel, Dolores (Cabuen˜es. Spain); Dr Mitov,
Ivan (Mu Sofia. Bulgaria); Dr Mlangeni, Dennis (Freiburg Uh.
Germany); Dr Montejo, Miguel (H Cruces. Spain); Dr Naaber,
Paul (Tartu U.C. Estonia); Dr Nohmans, Liesel (Gelderse Vallei
H. Netherlands); Dr Nonikov, Vladimir (Central Clin. Hospi-
tal. Russia); Dr Ozkan, Feriha (Ege University Medical Fac.
Turkey); Dr Papafrengas, Evangelos (Dgha Sismanoglion.
Greece); Dr Paradisi, Franco (Nuovo S. Giovanni Di Dio.
Italy); Dr Honderlick, Patrick (Hospital Foch. France); Dr
Paz Vidal, Isabel (Hospital Cristal. Spain); Dr Perea, Evelio
(H Virgen Macarena. Spain); Dr Cruaud, Philippe ( Jean
Verdier. France); Dr Pina, Elaine (H Capucho Desterro.
Portugal); Dr Pina, Teresa (Hospital Curry Cabral. Portugal);
Dr Pizzato, Enrico (Boldrini. Italy); Dr Pizzato, Enrico (Ospe-
dale Boldrini. Italy); Dr Platsouka, Evangelia and Dr Paniara,
Olga (GhEvangelismos. Greece); Dr Popova, Valentina (Uh
Pleven. Bulgaria); Dr Priv-Doz, Heinz-Michael (Institut Fur
Klinikhigien. Germany); Dr Pterocheilou-Paschou, Vassiliky
(Alexandra H. Greece); Dr Punda-Polic, Volga (Clinical
Hospital Split. Croatia); Dr Rafalsky, Vladimir (Smolensk
Regional Hospita. Russia); Dr Raga, Xavier (St.Pau I Sta.Tecla.
Spain); Dr Rene-Marc, Jolidon (Ch Yverdon. Switzerland); Dr
Ribeiro, Graca (Hu Coimbra. Portugal); Dr Romanyk,
Juan (Principe De Asturias. Spain); Dr Ruyer, Olivier (Ch
Belfort. France); Dr Ruzicka, Filip (St.Anna’s Hospital,
Brno. Czech Republic); Dr Samet, Alfred (Public Hospital
No1. Poland); Dr Sanfeliu, Isabel (Cs Parc Tauli. Spain);
Dr Sasca, Nabia (I.Diseases Hospital. Romania); Dr Schmidt,
Marianne (2nd Department of Of Pediatrics. Hungary); Dr
Sevillano, Joaquina (Povisa. Spain); Dr Shah, Pramod ( J.W.
Goethe H. Germany); Dr Sierra, Montse (H Barcelona. Spain);
Dr Simeckova, Eva (Strakonice Hospital Czech Republic); Dr
Simo´, Maria (Hospital De Terrassa. Spain); Dr Sion, Jean-Paul
(Monica Campus Efka. Belgium); Dr Soyletir, Guner (Marmara
University. Turkey); Dr Spencer, Robert (Bristol Royal Infirm-
ary. United Kindom); Dr Spiliopoulou, Iris (Uh Patras.
Greece); Dr Streharova, Anna (Uh Trnava. Slovak Republic);
Dr Su¨merkan, Bu¨lent (Erciyes University Hospital Turkey); Dr
Swoboda, Ewa (Cch Warsow. Poland); Dr Tambic Andrasevic,
Arjana (Uhid Dr Fran Mihalevic. Croatia); Dr Tomic, Viktorija
(U.C Of Respiratory Diseases. Slovenia); Dr Torrisi, Claudia
(Azienda Policlinico. Italy); Dr Tripkovic, Vesna (Uhc Rebro.
Croatia); Dr Trischler-Ceke, Zdenka (General Hospital
Vukovar. Croatia); Dr Trolin, Christine (Chei. Belgium); Dr
Tsoulfa,Soultana(GhG.Papanikolau.Greece);DrVackova,Marie
(Th Hradec Kralove. Czech Republic); Dr Van Griethuysen,
Arjanne (Hospital Rijnstate Arnhem. Netherlands); Dr
Vanhems, Philippe (Edouart Herriot Hospital. France); Dr
Vavtsi-Manou, Olympia (Theagenio Cancer H. Greece);
Dr Vazquez, Fernando (Monte Naranco. Spain); Dr Verstraete,
Roeland (Monica Olvmiddelares. Belgium); Dr Vidal, Francesc
(Hu Tarragona Joan XXIII. Spain); Dr Villar, Henar (H San
Agustin De Aviles. Spain); Dr Von Wolffen, Hinrik (Klinikum
Nord, AK Barmbeck and AK Wandsbek. Germany); Dr Von
Wulffen, Hinrik (Ak Wandsbek. Germany); Dr Voss, Andreas
(Umc St Radboud. Netherlands); Dr Wagenlehner, Florian
(St Elisabeth H. Germany); Dr Wagner, Jutta (Uk Benjamin
Franklin Fub.Germany);DrWeston,Vivienne (UhNottingham.
United Kindom); Dr Wisplinghoff, Hilmar (Hu Cologne.
Germany); Dr Wolfgang, Pramer (Kh Wels. Austria); Dr
Younes, Yasdanfard (Hvidovre Hospital. Denmark); Dr
Zimmer, Jeannot A. (Berlin Hospital. Germany).
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 523–531
Bouza et al European perspective on nosocomial urinary tract infections I 531
